Results 81 to 90 of about 12,110 (254)

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Frontiers in Psychiatry, 2020
The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate.
Max Wolff, Max Wolff, Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer, Henrik Jungaberle   +8 more
doaj   +1 more source

Pengaruh Lysergic Acid Diethylamide Yang Terdapat Pada Lem Eha-bond Terhadap Kualitas Spermatozoa Wistar Jantan (Rattus Norvegicus) [PDF]

, 2015
: Lysergic Acid Diethylamide (LSD) is a psychotropic drug that can be found in glue. This substance acts as serotonine and dopamine agonists and results in hallucinogenic effect.
Budiono, A. (Alfred), Satiawati, L. (Lusiana), Wantouw, B. (Benny)   +2 more
core  

Psychedelics Promote Structural and Functional Neural Plasticity. [PDF]

, 2018
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast ...
Barragan, Eden V, Burbach, Kyle F, Cameron, Lindsay P, Dennis, Megan Y, Duim, Whitney C, Gray, John A, Greb, Alexandra C, Ly, Calvin, McAllister, A Kimberley, Olson, David E, Ori-McKenney, Kassandra M, Paddy, Michael R, Soltanzadeh Zarandi, Sina, Sood, Alexander, Wilson, Paige C, Wong, Jonathan M   +15 more
core   +2 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Quel est l'impact potentiel du traitement du trouble lié à l’usage de l’alcool par le LSD : Une revue systématique d’essaies contrôlés randomisés, méthodes PRISMA

Cortica
Dans ce travail, l’objectif principal est d’explorer les effets et l’efficacité du diéthylamide de l'acide lysergique, plus communément connu sous le nom de LSD, dans le traitement du trouble lié à l’usage de l’alcool.
Maya Oberson
doaj   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Free energy calculations of the functional selectivity of 5-HT2B G protein-coupled receptor.

PLoS ONE, 2020
G Protein-Coupled Receptors (GPCRs) mediate intracellular signaling in response to extracellular ligand binding and are the target of one-third of approved drugs.
Brandon L Peters, Jinxia Deng, Andrew L Ferguson   +2 more
doaj   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source